Abstract
Animal studies show FC-23 to be a promising magnetic resonance imaging indicator of regional cerebral blood flow. In a Phase 1, dose ranging (investigative new drug) study, neuropsychological (NP) tests, subjective ratings, and intensive physiological monitoring were used to determine the maximum tolerated concentration of FC-23 for human application. Five normal healthy male volunteers were exposed to concentrations of FC-23 between 10% and 60% [randomly interleaved with exposures to both room air and 40% nitrous oxide (N2O)] in a within-subjects, double-blind design. Analyses of individual cases and ranked group data showed that individuals tolerated the 30% concentration of FC-23 according to established criteria. Planned comparisons indicated that inhalation of FC-23 produced smaller NP changes and fewer negative symptoms than 40% N2O but poorer NP performance and more negative symptoms than room air. This study indicated that FC-23 is not inert and that humans do not tolerate concentrations suitable for current MRI technology. NP and subjective data assisted in characterizing the sedative effect of FC-23. Copyright (C) 1998 Elsevier Science Inc.
Original language | English (US) |
---|---|
Pages (from-to) | 617-626 |
Number of pages | 10 |
Journal | Neurotoxicology and Teratology |
Volume | 20 |
Issue number | 6 |
DOIs | |
State | Published - Nov 1998 |
Externally published | Yes |
Keywords
- Computer-assisted tests
- Freon
- Neuropsychological tests
- Nitrous oxide
- Subjective effects
- Trifluoromethane
ASJC Scopus subject areas
- Toxicology
- Developmental Neuroscience
- Cellular and Molecular Neuroscience